ƒvProtein kinases are now firmly established as the largest group of drugable enzyme targets and the second largest family of targets for therapeutic drug discovery after G proteincoupled receptors. IBC's 7th Annual Protein Kinase Targets conference will highlight remarkable progress, challenges and opportunities in this area. The presentations from industry leaders will include case studies and strategies for improved kinase target and therapeutic drug discovery and validation.

Learn the latest on:

• Off target effects of existing clinical candidates
• Structure & non-classical site binding
• Toxicology vs. selectivity

Scientific Advisory Board

• Jessie M. English, Ph.D., Senior Director, Oncology Site Lead, Merck External Basic Research
• Scott Jakes, Ph.D., Director, Dept. of Cardiovascular Diseases, Boehringer Ingelheim Pharmaceuticals Inc.
• Steven Pelech, Ph.D., President and CSO, Kinexus Bioinformatics Corporation; Professor, Department of Medicine, University of British Columbia
• Patrick P. Zarrinkar, Ph.D.,Vice President, Technology Development, Ambit Biosciences

View the Agenda

• Day One
• Day Two
• Day Three

View the other Tracks

• Assay and Screening Advances
• G-Protein Coupled Receptors
• Ion Channel Targets